TD stands for tardive dyskinesia, a movement disorder that causes involuntary, repetitive motions of the face, tongue, limbs, or trunk. It develops as a side effect of certain medications, most commonly antipsychotics, that block dopamine receptors in the brain. Roughly 20 to 50 percent of people taking antipsychotics long-term develop some degree of TD.
What Causes Tardive Dyskinesia
Certain medications work by blocking dopamine receptors in the brain. Dopamine is a chemical messenger involved in controlling movement, mood, and motivation. When these receptors are blocked for months or years, they can become overly sensitive, essentially overreacting to normal amounts of dopamine. That hypersensitivity disrupts the brain’s ability to coordinate smooth, intentional movement, producing the involuntary motions characteristic of TD.
The medications most commonly responsible are older antipsychotics (sometimes called first-generation or “typical” antipsychotics) such as haloperidol, chlorpromazine, and fluphenazine. These drugs are prescribed for schizophrenia, bipolar disorder, and other psychiatric conditions. Newer antipsychotics carry a lower risk but are not entirely safe from causing TD either.
One non-psychiatric medication also linked to TD is metoclopramide, a drug used to treat slow stomach emptying (gastroparesis). Because it works through the same dopamine-blocking mechanism, long-term use carries similar movement-related risks.
A diagnosis of drug-induced TD generally requires at least three months of exposure to the causative medication. For people over 60, the threshold drops to one month.
How TD Looks and Feels
The most recognizable form of TD involves the face and mouth. You might notice repetitive lip smacking, puckering, or pouting. The tongue may twist, protrude, or dart in and out involuntarily. Chewing motions, jaw clenching, and facial grimacing are common. These movements tend to be irregular in timing and can vary in intensity from barely noticeable to severe enough to interfere with eating and speaking.
TD is not limited to the face. It can affect the arms, hands, legs, and feet with slow, snakelike writhing or rapid, jerky motions. Finger wiggling, toe tapping, and foot squirming are typical. The trunk can also be involved, producing rocking, twisting, or squirming of the hips and shoulders. In some cases, jerking movements of the abdomen and diaphragm create breathing irregularities.
Several less common variants exist. Tardive dystonia, which occurs in about 1 to 2 percent of long-term patients, causes sustained abnormal postures of the neck, face, or limbs rather than repetitive movements. Tardive akathisia produces an intense inner restlessness and a constant urge to move, leading to pacing and fidgeting. Some people develop a rhythmic tremor affecting the limbs, head, or voice. Forced, repetitive eye blinking (tardive blepharospasm) is another possibility.
Who Is Most at Risk
Age is the strongest risk factor. People over 55 are significantly more likely to develop TD, and they can develop it after shorter exposure to the triggering medication. Women appear to be at higher risk than men, particularly after menopause. Other factors that increase vulnerability include having a mood disorder alongside schizophrenia, a history of substance use, diabetes, and previous episodes of acute movement side effects early in treatment.
Higher doses and longer durations of dopamine-blocking medications raise the risk further, which is why clinical guidelines emphasize using the lowest effective dose for the shortest time possible.
How TD Is Diagnosed
There is no blood test or brain scan for TD. Diagnosis relies on a clinical exam and a tool called the Abnormal Involuntary Movement Scale, or AIMS. During an AIMS assessment, a clinician observes and rates involuntary movements across seven body areas: facial expression muscles, lips, jaw, tongue, upper extremities, lower extremities, and the trunk (including the neck, shoulders, and hips). Each area is scored from 0 (no movement) to 4 (severe).
The exam also captures how much the movements interfere with daily life and whether you are aware of them. Some people with mild TD don’t notice their own movements at all, while others find them distressing and disabling. Clinicians performing regular AIMS screenings can catch TD early, when it is more likely to respond to intervention.
Treatment and Management
The first step when TD is identified is reassessing the medication causing it. If the triggering drug can be reduced or stopped, that is the preferred approach. However, many people with serious psychiatric conditions cannot safely discontinue their antipsychotic. In those cases, switching to a newer antipsychotic with a lower risk profile, such as clozapine, may help.
One important caution: symptoms can temporarily worsen when the causative drug is reduced or withdrawn. Conversely, increasing the dose can temporarily mask TD movements, but this is not a viable long-term strategy because it ultimately worsens the underlying problem.
Two medications are specifically approved to treat TD. Both work by reducing the amount of dopamine (and related chemical messengers) available in the brain, calming the overactive movement signals. These treatments don’t cure TD, but they can meaningfully reduce the severity of involuntary movements for many people. Your prescriber can determine whether you are a candidate based on the severity of your symptoms and your overall treatment plan.
Can TD Go Away on Its Own
This is one of the more sobering realities of the condition. Older medical literature suggested TD was often reversible once the offending medication was stopped, but more recent data paints a different picture. A study from a university movement disorder clinic found that only about 13 percent of patients experienced full resolution of their symptoms after the triggering drug was completely withdrawn. Just 2 percent improved without any additional medical treatment.
Even among patients whose TD was caused by newer antipsychotics, the reversal rate was only about 20 percent. Many people did see some improvement in severity over time, but full resolution remained uncommon. The longer TD has been present before the medication is stopped, the less likely it is to fully reverse.
This is precisely why prevention matters so much. Guidelines recommend using the lowest effective dose of any dopamine-blocking medication for the shortest necessary period, with regular reassessment of whether the drug is still needed. Routine movement screening with the AIMS exam allows early detection, when reducing or changing the medication has the best chance of preventing permanent symptoms.